With MRSA becoming the "new normal" in many areas, clinicians will have to define the role of up to a dozen anti-MRSA drugs. Alternatives to vancomycin include older drugs like clindamycin, doxycycline, and trimethoprim/sulfamethoxazole, and newer agents like linezolid and daptomycin for serious infections. There are also a number of drugs under development including enhanced glycopeptides—dalbavancin, oritavancin, telavancin, and anti-MRSA cephalosporins.
